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Abstract
Background: The programmed cell death-1 receptor/programmed cell death-1 ligand (PD-1/PD-L1) pathway plays a crucial
role in tumor evasion from host immunity. This study was designed to evaluate the association between circulating PD-L1/
PD-1 and prognosis after cryoablation in patients with HBV-related hepatocellular carcinoma (HCC).
Methodology/Principal Findings: In the present study, 141 HBV-related HCC patients were enrolled and of those 109
patients received cryoablation. Circulating PD-L1/PD-1 expression was tested by flow cytometry, and 23 patients were
simultaneously evaluated for intratumoral PD-L1 expression by immunohistochemical staining. Circulating PD-1/PD-L1
expression was associated with severity of diseases in patients with HCC, and the circulating PD-L1 expression was closely
correlated with intratumoral PD-L1 expression. Of the clinical parameters, PD-1/PD-L1 expression was associated with tumor
size, blood vessel invasion and BCLC staging. Moreover, PD-1/PD-L1 expression dropped after cryoablation while being
elevated at the time of tumor recurrence. Patients with higher expression of circulating PD-L1, as well as circulating PD-1,
had a significantly shorter overall survival and tumor-free survival than those with lower expression. Multivariate analysis
confirmed that circulating PD-L1 could serve as an independent predictor of overall survival and tumor-recurrence survival
in HCC patients after cryoablation.
Conclusions/Significance: Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in
patients with HBV-related hepatocellular carcinoma.
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Introduction
Hepatocellular carcinoma (HCC) is a complex condition with
multiple variables affecting the disease course and response to
treatment, including liver function and performance status of the
patient and tumor stage [1,2]. Patients with hepatitis B or hepatitis
C virus infection are also at a higher risk of developing HCC, and
over 85% of patients with HCC present with HBV infection in
China [3]. Surgical treatment options for patients with HCC
include resection and liver transplantation[4,5]. Local ablation,
such as cryoablation like surgery, is also considered as a potentially
curative therapy [6]. This technique has the advantages of being
minimally invasive, exerting fewer effects on liver function, and
shows better reproducibility and improved immunity following
treatment as compared with traditional surgical approaches. Our
previous study [7] indicate that cryoablation not only directly
destroys the malignant tissues, but also exerts effects on the tissue
adjacent to the carcinoma. Yantorno et al. [8] and Shulman et al.
[9] have postulated that cryoablation interferes with the biological
activity of tumor cells while preserving the structure of tumor
antigenic proteins, which may enhance the specific anti-tumor
immune response. Sabel et al. [10,11] used cryoablation in BALB/
c mice with MT-901 mammary adenocarcinoma tumors and
reported that cryoablation led to the induction of both a tumor-
specific T-cell response in the tumor-draining lymph node and
increased systemic NK cell activity. These observations were
correlated with tumor rejection upon re-challenge in mice that had
undergone cryoablation. Osada et al. [12] performed cryoablation
in 13 HCC patients with unresectable tumors. Following
treatment, not only was the local tumor found to be necrotic,
but the adjacent tumor tissue was also necrotic and shrunken,
which was regarded as ectopic tumor suppression. This response
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host production of anti-tumor antibodies [13].
Programmed cell death-1 receptor (PD-1), a novel co-inhibitory
receptor mainly expressed on activated T and B cells [14], belongs
to the CD28 family, with 28% identity to the extracellular region
of CTLA-4 [15,16]. Programmed cell death-1 ligand (PD-L1, also
known as B7-H1), the ligand of PD-1, can be induced in
monocytes, dendritic cells, and parenchymal cells under the
stimulation with proinflammatory cytokines, such as type-I and
type-II interferons [17]. There is growing evidence to show that
PD-L1 can deliver an inhibitory signal to PD-1 expressing T cells,
leading to suppression of the immune response by inducing
apoptosis, anergy and functional exhaustion of T cells, which
subsequently contributes to the compromised tumor immunity
[18]. Until now, the relationship between intratumoral PD-L1 and
tumor aggressiveness, and clinicopathological features as well as
overall survival has been well described in several human
malignancies, such as ovarian, esophageal and pancreatic cancer
[19-21]. A recent report demonstrated that HCC patients with
higher expression of intratumoral PD-L1 had a significantly
poorer prognosis than that of HCC patients with lower expression
in the overall survival time after resection. [22]. Our previous
report [23] showed PD-1 and PD-L1 upregulation promotes
CD8
+T-cell apoptosis and post-operative recurrence in HCC
patients. However, the detection of intratumoral PD-L1 requires
an invasive operation for liver biopsy and would be a complex test
for clinical applications, and there have been few reports on
changes in circulating PD-L1/PD-1 levels in patients with HCC
before and after cryoablation. Therefore, the present study was
designed to investigate the association between cryoablation and
circulating PD-L1/PD-1 variation in patients with HCC and to




In total, 141 patients with HBV-related HCC were enrolled in
this study from January 2006 to January 2009. Based on the
Barcelona Clinic Liver Cancer (BCLC) staging classification [24],
46 patients wereclassifiedasstage A,63 asstage B,and 32 as stage C
(Table 1). Except for the patients at stage C, the 109 remaining
patients received curative treatment with complete cryoablation
lesions initially by dynamic spiral computed tomography or
contrast-enhanced dynamic magnetic resonance imaging and were
followed-up. All 109 patients had received no prior treatment such
as chemotherapy or radiation therapy. Individuals with concur-
rence of autoimmune disease, HIV and syphilis were excluded. The
decision whether to include these patients into this study was made
by a multidisciplinary team of doctors coming from different
departments. The study protocol was approved by the Beijing 302
Hospital Research EthicsCommittee,and written informed consent
was obtained from the patients who met the inclusive criteria prior
to blood and tumor sampling. The primary follow-up endpoint of
the study was tumor-free survival time (TFS). The secondary
endpoint was overall survival time(OS). TFS was calculated from
the date of commencement of cryoablationto the date of recurrence
HCC. OS was calculated from the date of commencement of
cryoablation to the date of death or last follow-up.
Argon–helium cryoablation and sample collection
Argon–helium cryoablation was followed as our previously
described [25]. Briefly, argon-helium gas based CRYOcare system
(EndoCare,Irvine, CA, USA) and cryoprobes were used to freeze
the tumor with a dual freeze-thaw cycle under ultrasound-guiding.
The size and number of probes depended on the location and size
of the lesions to be ablated. A single 15-minute freeze was
performed, followed by a passive thaw. The iceball dimensions
were monitored via intraoperative ultrasonography. Cryoprobe
temperatures were reduced in 1 minute to 2135uC62uC. We
carried out ablation of all tumors with a curative intent, with a
margin of 1 cm beyond the edge of the tumor if feasible, in a single
cryoablation. The procedure was performed with the patient
under conscious sedation. Liver function tests, a-fetoprotein (AFP)
detection, and abdominal computed tomography (CT) or
magnetic resonance imaging (MRI) were performed regularly.
Anti-coagulated blood (heparin) was obtained 1 day before
treatment and 1, 4weeks after treatment. A singleaction Biopsy-
device (Promex Technologies, Franklin, IN, USA) was used during
the operation with ultrasound guidance, and biopsy of the tumor
tissue was performed in 23 patients.
Flow cytometric analysis
Antibodies conjugated with different fluoresceins, including
fluorescein isothiocyanate (FITC), phycorerythrin(PE), peridin
chlorophyll protein (PerCP) and allophycocyanin (APC) were
used for flow cytometric analysis. PE-conjugated anti-PD-1, PD-
L1 and APC-conjugated anti-CD14 were purchased from
eBiosciences (San Diego, CA,USA); PerCP-conjugated anti-CD8
and APC-conjugated anti-CD3 were purchased from BD
Biosciences (San Jose, CA,USA). In detail, PE-conjugated anti-
PD-L1 and APC-conjugated anti-CD14 were applied for the PD-
L1 detection on monocytes; PE-conjugated anti-PD-1, PerCP-
conjugated anti-CD8 and APC-conjugated anti-CD3 were used
for the PD-1 detection on CD8+T cells. To determine of positive
expressions of PD-1 and PD-L1, PE-conjugated IgG1 (eBios-
ciences) were adopted in this assay. For each test, 50 ml fresh
heparinized peripheral blood was incubated with indicated
antibodies (20 ml) for 20 min and then lysed with FACS
TM lysing
solution (BD Biosciencs, San Jose, CA, USA), washed with PBS,
fixed and analyzed by the fluorescence activated cell sorting
(FACS) analysis (FACS Calibur, BD Biosciences, San Jose, CA,
USA). Data were analyzed by Flowjo software (TriStar, San
Carlos, CA, USA).
Immunohistochemical staining for PD-L1 evaluation in
liver tissues
Based on the availability within all 141 HCC patients, there
were twenty-three patients enrolled in this study by simultaneously
collecting peripheral blood and liver tumor biopsy, which included
Table 1. Basic clinical features of 141 patients with hepatitis
B-related HCC.
Clinical factor Stage A Stage B Stage C
Cases 46 63 32
Age (years) 53.1(35–68) 52.9(28–70) 52.8(36–71)
Male/Female 33/13 45/18 31/1
Tumor diameter (cm) 2.1(0.5–3) 4.5(3–6) 6.8(5–9)
AFP level$20,20 24/22 40/23 22/10
HBV DNA (-/,10
5$10
5) 20/12/14 17/22/24 10/16/6
Child-Pugh (A/B) 33/13 42/21 20/12
HCC, hepatocellular carcinoma; AFP, a-fetoprotein; HBV, hepatitis B virus.
doi:10.1371/journal.pone.0023621.t001
Circulating PD-1/PD-L1 in HCC Patients
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e236219 stage A, 8 stage B and 6 stage C patients in detail. Paraffin-
embedded, formalin-fixed liver tissue from these enrolled HCC
patients was cut into 5-mm sections and placed on polylysine-
coated slides. Antigen retrieval was achieved via pressure cooking
for 10 minutes in citrate buffer. Mouse monoclonal anti-human
PD-L1 antibody (Biolegend, San Diego, CA, USA) was used. 3-
amino-9-ethyl-carbazole (red color) was used as a substrate
followed by counterstaining with hematoxylin. For the evaluation
of PD-L1 staining, three independent pathologists examined the
slides without access to clinical information. The intensity of the
PD-L1 staining was scored as one of four degrees according to the
area of positive staining, including score 0, less than 25%; score 1,
25%–50%; score 2, 50%–75%; and score 3, higher than 75%.
The results for score 0 and 1 were considered as low PD-L1
expression, whereas score 2 and 3 were considered as high PD-L1
expression, accordingly.
Statistical analysis
Data were summarized and presented as means 6 SD and
analyzed using SPSS13.0 software (SPSS Inc, Chaicago, IL,USA).
The Mann–Whitney nonparametric U-test was applied for com-
parisons between 2 groups and the Kruskal–Wallis nonparametric
H-test was performed for comparisons among multiple groups. The
x2 test was used for comparison of the individual variables. The
Wilcoxon matched-pairs test was used to compare the data from the
same individuals. Receiver operating characteristic (ROC) curve
analysis was used to determine the OS predictive value of the
parameters, and the differences in the area under the curve (AUC)
were detected by using SPSS13.0.Tumor recurrence and survival
rates were analyzed by the Kaplan–Meier method. The log-rank test
was applied to compare findings among groups. The Cox regression
model was used to perform univariate and multivariate analyses. A
value of P,0.05 was considered to be statistically significant.
Results
Upregulated circulating PD-L1/PD-1 expression is related
to HCC progression
We firstly investigated the circulating PD-L1/PD-1 expression
by using flow cytometric analysis in a cohort of 141 HCC patients.
The gating strategies for both types of expression are shown
(Fig. 1A and 1C). Our results revealed that the circulating PD-L1
expression in monocytes increased from stage A to stage B (Fig. 1B;
vs. stage A, P,0.001) and reached the highest level at stage C
(Fig. 1B; vs. stage A, P,0.001; vs. stage B, P=0.014). Moreover,
the circulating PD-1 exhibited a similar expression profile to PD-
L1 (Fig. 1D; stage B vs. stage A, P,0.001; stage C vs. stage A,
P,0.001; stage C vs. stage B, P=0.011). Therefore, circulating
Figure 1. Gating strategies and expression profiles of circulating PD-L1 and PD-1 in 141 patients with HBV-related HCC. The gating
strategies and representative results of circulating PD-L1 (A) and PD-1 (C) expression are shown. FSC, forward scatter; SSC, side scatter. In the
histogram, the black line indicates PD-L1 or PD-1, whereas the grey line represents its corresponding isotype control. Numbers in the histograms
show the frequencies of positive cells. The statistical results for circulating PD-L1 (B) and PD-1 (D) were organized according to the HCC stages (stage
A, n=46; stage B, n=63; stage C, n=32), respectively. The black bar indicates the mean value.
doi:10.1371/journal.pone.0023621.g001
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patients with HCC.
As a previous report demonstrated that intratumoral PD-L1 was
significantly associated with overall survival in HCC patients [22],
we compared the expression levels between intratumoral and
circulating PD-L1. According to the staining area and intensity,
we scored the intratumoral PD-L1 expression as one of four levels
of degree, from score 0 to score 3 (Fig. 2A). Within a total of 23
HCC patients, we found circulating PD-L1 expression was closely
correlated with their corresponding intratumoral PD-L1 expres-
sion (Fig. 2B; r=0.706, P,0.001). We also noticed a tendency for
the intratumoral PD-L1 expression that the stage A patients are
preferentially showing a score 0-1, compared with score 3 for stage
C patients (Fig. 2A). Furthermore, ROC curves were used to
compare that intratumoral PD-L1 and circulating PD-1/PD-L1,
and to determine which one was a better parameter to predict the
OS prognosis of the HBV-associated liver cancer patients. The
results showed that although the area of intratumoral PD-
L1(0.8060.10, 95%CI:0.58–O.94) was higher than that of
circulating PD-L1(0.7560.11, 95%:0.52–0.90,P=0.55) and lower
than circulating PD-1 (0.8760.08, 95%;0.67–0.97,P=0.56), there
were no statistic difference(Fig. 2C).
Correlations between circulating PD-1/PD-L1 expression
and clinical parameters in patients with HCC
Patients with HCC (n=141) were divided into 2 groups
according to the median of circulating PD-1/PD-L1 expression:
those with low PD-1/PD-L1 expression (,10.88%/9.18) and
those with high PD-1/PD-L1 expression ($10.88%/9.18). Upon
analysis, tumor size, blood vessel invasion and BCLC staging were
associated with PD-1/PD-L1 expression. However, no significant
relationships were found between PD-1/PD-L1 expression and
gender, age, number of tumors, HBV DNA load, AFP level or
Child-Pugh class (Table 2).
Dynamic circulating PD-1/PD-L1 variation after
cryoablation
The results of the analyses showed that circulating PD-1/PD-L1
expression in 109 HCC patients increased significantly 1 week
after cryoablation when compared with that prior to treatment,
and liver function impairment was observed at 1 week after
treatment. The measure of liver function reached normal within 4
weeks after treatment (Table 3), accompanied by decreased PD-1/
PD-L1 expression (Fig. 3C,3D). In addition, studies of patients
Figure 2. Circulating PD-L1 expression was closely correlated with their corresponding intratumoral PD-L1 expression.
(A)Representative immunohistochemical results of PD-L1 for different degrees are shown(red for PD-L1, 6400). (B) Statistical analysis demonstrated
that circulating PD-L1 was significantly correlated with intratumoral PD-L1(r=0.706, P,0.001). (C) The predictive ability of circulating PD-L1/PD-1
compared with that of intratumoral PD-L1 by receiver operating characteristic (ROC) curves for overall survival (OS).
doi:10.1371/journal.pone.0023621.g002
Table 2. Correlation between circulating PD-L1/PD-1
expression and clinical features of 141 HCC patients.
PD-L1 PD-1
Characteristics Low High P Low High P
Age (years)
$54 38 35 0.346 35 38 0.945
,54 30 38 33 35
Gender
Male 50 59 0.302 50 59 0.179
Female 18 14 19 13
AFP (ng/ml)
$20 40 46 0.610 38 48 0.105
,20 28 27 32 23
Tumor size (cm)
$33 2 6 3 #0.001 31 64 #0.001
,33 6 1 0 3 9 7
Tumor number
Single 43 39 0.238 47 35 0.051
Multiple 25 34 24 35
Child-Pugh
A 48 47 0.432 48 47 0.764
B2 0 2 6 2 2 2 4
Vascular invasion
Yes 6 26 0.001 7 25 0.001
No 60 49 63 46
HBV DNA (U/ml)
negative 21 26 0.925 27 20 0.314
,10
5 24 26 21 29
$10
5 20 24 22 22
BCLC staging #0.001 #0.001
Stage A 36 10 38 8
Stage B 26 37 25 38
Stage C 6 26 7 25
X
2 tests for all analysis.
doi:10.1371/journal.pone.0023621.t002
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prevalence of circulating PD-1/PD-L1 individually increased
compared with the periods without tumors(4weeks after cryoabla-
tion) (Fig. 3A, 3B, E, F).
Increased prevalence of circulating PD-1/PD-L1 predicts
poor prognosis in HCC patients after cryoablation
For the 109 patients followed up for a median of 23 month-
s(6,36months) after the cryoablation, the 1-, 2- and 3-year survival
rate was 86%, 75% and 67%, respectively. Furthermore, the 1-, 2-
and 3-year recurrence-free survival rate was 70%, 58% and 40%,
respectively.To address whether increased circulating PD-1/PD-L1
was associated with prognosis in HCC patients after cryoablation,
46 HCC patients at stages A and 63 HCC patients at stage B were
divided into 2 groups by the median value of circulating PD-1/PD-
L1 at the time before treatment as low PD-1 (n=23, 4.0561.28%
for stageA; n=31, 9.2661.63% for stage B) and high PD-1 (n=23,
9.2663.09% for stage A; n=32, 18.0563.78% for stage B), low
PD-L1 (n=23, 4.26+0.93% for stageA; n=31, 7.1762.19% for
stage B) and high PD-L1 (n=23, 8.51+2.48% for stage A; n=32,
19.3769.41% for stage B). The results showed that the high PD-1/
PD-L1 group had a significantly higher rate of tumor recurrence
and progression after cryoablation in comparison to the low PD-1/
PD-L1 group (Fig. 4). The univariate analysis (Table 4) showed that
the overall survival was associated with PD-1 and PD-L1. The
recurrence-free survivalwasrelated totumorsize, PD-1andPD-L1.
Multivariateanalysis(Table5)using the Coxhazard modelrevealed
that the circulating PD-L1 expression was independent poor
prognostic factors for TFS and OS, and PD-1 expression was
independent poor prognostic factor for TFS.
Discussion
The interaction between PD-1 and PD-L1 has been demon-
strated to negatively regulate T-cell activation and functions,
leading to inhibition of the immune responses in cancer patients
[16,26,27]. In addition, patients with PD-L1-positive cancer cells
were reported to have a significantly poorer prognosis than those
with PD-L1-negative cancer cells in pancreatic cancer, urothelial
cancer, breast and ovarian cancer patients [16,18,21,28]. Two
recent reports demonstrated that PD-L1 expressed in tumor cells
or peritumoral activated monocytes contributed to tumor
aggressiveness and postoperative recurrence in hepatocellular
carcinoma patients [22,29]. These investigations indeed provided
new evidences for disease diagnosis and prognosis evaluation.
However, the invasive collection for liver biopsy makes the whole
procedure much complex and inconvenient. Therefore, it seemed
worth evaluating the clinical significance of circulating PD-L1 in
predicting the disease progression.
In the present study, we detected PD-L1/PD-1 expression on
circulating peripheral blood mononuclear cells(PBMCs) and found
PD-L1/PD-1 expression increased with liver tumor progression.
Further study revealed that there was a close correlation between
the circulating and intratumoral PD-L1 expression. We analyzed
the circulating PD-1/PD-L1 expression and the clinical parame-
ters in patients with HCC. The result demonstrated that tumor
size, blood vessel invasion and BCLC staging were associated with
PD-1/PD-L1 expression. However, no significant relationships
were found between PD-1/PD-L1 expression and gender, age,
number of tumors, HBV DNA load, AFP level or stage of liver
function. Although several publications demonstrated that PD-1/
PD-L1 expression levels correlated with the HBV DNA titers
[30,31], we did not find any correlations in the present study
regarding HCC patients with chronic HBV infection. Besides
monocytes, PD-L1 is also expressed in dendritic cells and our
previous investigations also revealed a good correlation for PD-L1
expression between these two kinds of cells [23]. However, we
abandoned the dendritic cell-associated PD-L1 in the present
study due to its more complex detection procedures and more
expensive cost.
Our observations suggested that elevated PD-1/PD-L1 expres-
sion during the first week after cryoablation was related to
inflammation caused by the therapy and that postoperative fever
and liver function impairment were the main manifestations. A
previous study reported that inflammation could promote PD-1/
PD-L1 expression [30]. Subsequent reduction of PD-1/PD-L1
expression 4 weeks after therapy was associated with a recovery
from stress and the reduction of tumor burden. Additionally,
numerous tumor antigens are released from these necrotic cells,
resulting in an immune response and reduction in immune
tolerance [8,9]. Interestingly, Campbell et al [32] found that
cryopreservation of PBMC led to a marked reduction of PD-1 and
PD-L1 expression in CD3+/CD8+ T cells and CD45+/CD14+
monocytes, with no significant effect on CD3+CD4+ T cells. The
previous study [22,23] suggested that intratumoral PD-L1 was
closely associated with the recurrence or metastasis of HCC after
surgery, and we compared the circulating PD-1/PD-L1 expression
before and after tumor recurrence in 11 HCC patients received
cryoablation.The result showed that PD-1/PD-L1 expression was
elevated aftertumorrecurrence. Inaninvitrostudy,Chen J etal[33]
found that hepatoma cells up-regulate expression of programmed
cell death-1 in T cells.Based on the dynamic circulating PD-1/PD-
L1 variation after cryoablation and Chen’s finding [33], we support
the mechanism that PD-1/PD-L1 upregulation may be due to
cytokine stimulations in the tumor microenvironment [29].
Growing investigations demonstrate that PD-1 extensively up-
regulated on tumor Ag-specific T cells in cancer patients and play
a crucial role in the mechanism of tumor evasion by inhibiting the
proliferation, cytokine-secretion and cytoxicity of tumor Ag-
specific T cells [34-36]. Especially, Our previous study show that
the interaction between PD-1 and intratumoral PD-L1 promote
the apoptosis of CD8+ T cells, which probably contribute to the
low expression of tumor Ag-specific T cells in patients with
hepatocellular carcinoma [23]. There are two main pathways
Table 3. Hepatic function of 109 HCC patients before and after cryoablation.
Weeks ALB (g/L) ALT (U/L) AST (U/L) TBIL (mol/L) PA (%)
Baseline 38.7564.31 42.33622.14 48.25616.17 20.38612.17 87.08612.31






43 7 . 5 4 66.32 38.52615.41 44.12618.23 18.1168.92 86.2611.32
*: P,0.05 versus baseline.ALB, albumin; ALT, alanine aminotransferase; AST aspartate aminotransferase; TBIL, total bilirubin; PA, prothrombin activity.
doi:10.1371/journal.pone.0023621.t003
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tumors (n=11, PR, post-recurrence)showed that circulating PD-1/PD-L1 expression individually increased 4 weeks after cryoablation (PC, post-
cryoablation). (C,D)Circulating PD-1/PD-L1 expression in 109 HCC patients increased significantly 1 week after cryoablation when compared with that
before treatment, and dropped 4 weeks later. (E)A HCC patient(stageA, E1) receiving cryoablation showed tumor completely necrosis one week
later(E2) and the necrotic tumor tissue shrank 33 months later with no tumor recurrence(E3). (F) A HCC patient(stageB, F1) receiving cryoablation
showed tumor completely necrosis one week later(F2) and tumor recurred at the margin of necrotic tumor tissue 18 months later(F3, arrow indicates
the recurred tumor).
doi:10.1371/journal.pone.0023621.g003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e23621Figure 4. Increased expression of circulating PD-L1/PD-1 predicts poor prognosis in HCC patients after cryoablation. 109 HCC
patients were divided into 2 groups by the median value of circulating PD-1/PD-L1 at the time before treatment as low PD-1 (n=23, 4.0561.28% for
stageA; n=31, 9.2661.63% for stage B) and high PD-1 (n=23, 9.2663.09% for stage A; n=32, 18.0563.78% for stage B), low PD-L1 (n=23,
4.26+0.93% for stageA; n=31, 7.1762.19% for stage B) and high PD-L1 (n=23, 8.51+2.48% for stage A; n=32, 19.3769.41% for stage B). (A,B)HCC
patients in stage A with lower expression of circulating PD-1 have longer TFS and OS than those with higher expression(P=0.03 and
P=0.002,respectively). (C,D) HCC Patients in stage B with lower expression of circulating PD-1 have longer TFS and OS than those with higher
expression(P=0.002 and P=0.045,respectively). (E,F)HCC patients in stage A with lower expression of circulating PD-L1 have longer TFS and OS than
those with higher expression(P=0.004 and P=0.004,respectively). (G,H)HCC patients in stage B with lower expression of circulating PD-L1 have
longer TFS and OS than those with higher expression(P=0.000 and P=0.005,respectively).
doi:10.1371/journal.pone.0023621.g004
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specific stimulation; the other is by the cytokine pathway, through
which PD-1 upregulations are promoted on non-tumor Ag-specific
T cells. Here, we propose that the upregulation of PD-1 on non-
tumor Ag-specific T cells should constrain the tumor-associated
inflammation to a much milder degree, which hereafter favor the
tumor differentiation and proliferation. However, further investi-
gations should be carried out to elucidate the detailed mechanism
of this issue.
In the present study, we also found patients with recurrent
tumors, which would generally be smaller than primary ones,
associated with higher PD-1/PD-L1 expression. According to
former investigations, we believe that it is the tumor-associated
inflammation, rather than tumor volume, which promote the
elevated expression of PD-1 and PD-L1. After cryoablation
therapy, tumor cells were degenerated, disaggregated and up-
taken by antigen presenting cells, e.g. kuffer cells, pDC and mDC,
which lead to the secretion of a large mount of proinflammatory
cytokines, including IFN-a,IFN-c and gamma-chain cytokines. In
detail, interferons could promote PD-L1 expression on both tumor
cells and antigen presenting cells in comparison with that gamma-
chain cytokines account for PD-1 elevations on CD8+T cells.
Thus, both PD-1 and PD-L1 expression was significantly up-
regulate at the first week post-cryoablation. Together with the
resolution of tumor burden, the immune system goes in to a
quiescent phase (4w after cryoablation), manifesting lower PD-1
and PD-L1 expression. When recurrence occurs, the immune
system should be re-activated and promote an inflammation, both
of which favor PD-1 and PD-L1 re-elevation, in comparison with
the expression at week 4 post cryoablation therapy, at the time
when patients are free of tumor burden.
Recurrence after hepatectomy or ablation is one of main
biological features of HCC. Tumor diameter,portal vein tumor
thrombus, microvessel invasion, and tumor capsule invasion are
the main high risk factors for early recurrence [37]. Identifying the
high risk associated with early recurrence contributes to the grasp
of operation indications and guidance for adjunctive therapy. The
cryoablation approach is similar in therapeutic efficacy and
recurrence rate to hepatic resection and radiofrequency ablation
(RFA) [38,39]. In the present study, we found that the high PD-1/
PD-L1 group had a significantly higher tumor recurrence or
progression rate after cryoablation compared with the low PD-1/
PD-L1 group. As the patients received cryoablation were at stage
A and stage B, so the well-established factors including tumor
vascular invasion and TNM stage were excluded from multivariate
analyses.Since the sample size of the present study was limit-
ed,further studies are needed to draw valid conclusion for the
prognostic factors. Moreover, the multivariate analyses showed
PD-L1 seemed to be a much stronger predictor than PD-1,
regarding that PD-L1 is the independent predictor for both TFS
and OS in comparison to PD-1 for TFS only. Mechanically, it is
not easy to explain the difference between PD-L1 and PD-1 on
this issue. However, we propose that PD-L1 should be much more
sensitive to take changes according to the inflammatory intensity,
due to its innate role to protect host from overwhelming
inflammation through engagement with PD-1. Thus, the PD-L1
expression seems to be more accurate to reflect the inflammatory
changes which are associated with tumor progression.
Many mechanisms have been proposed for an attenuated
immune response to tumors, including partial antigen masking,
failure in antigen processing, suppression of effector cells and
inadequate costimulation [40-42]. In the current study, we showed
Table 4. Univariate analyses of prognosis factors associated with survival in 109 HCC patients of stage A/B.
Variables TFS OS
HR(95%CI) P HR(95%CI) P
Age, y($54 vs ,54) 0.709(0.446,1.126) 0.145 0.757(0.436,1.314) 0.322
Gender(male vs female) 0.853(0.504,1.442) 0.552 0.743(0.388,1.423) 0.371
AFP, ng/ml($20 vs ,20) 1.182(0.739,1.891) 0.485 1.225(0.694,2.161) 0.484
Tumor size, cm($3v s,3) 2.033(1.232,3.353) 0.005 1.654(0.915,2.991) 0.096
Tumor number($2 vs 1) 1.363(0.853,2.175) 0.195 1.576(0.910,2.730) 0.105
Child-Pugh(A vs B) 0.858(0.522,1.410) 0.545 0.694(0.373,1.290) 0.248
HBV DNA, U/ml(negative vs ,10
5 vs $10
5) 0.961(0.729,1.267) 0.779 0.832(0.592,1.168) 0.287
PD-1(low vs high) 2.683(1.666,4.322) #0.001 2.710(1.498,4.901) 0.001
PD-L1(low vs high) 4.290(2.607,7.059) #0.001 3.180(1.755,5.759) #0.001
Note: Cox proportional hazards regression model.
doi:10.1371/journal.pone.0023621.t004
Table 5. Multivariate analyses of prognosis factors associated with survival in 109 HCC patients of stage A/B.
Variables TFS OS
HR(95%CI) P HR(95%CI) P
Tumor size, cm($3v s,3) 0.744(0.390,1.423) 0.372 0.740(0.366,1.495) 0.402
PD-1(low vs high) 1.811(1.011,3.245) 0.046 1.948(0.96,3.955) 0.065
PD-L1(low vs high) 3.891(2.151,7.041) #0.001 2.650(1.300,5.401) 0.007
Note: Cox proportional hazards regression model.
doi:10.1371/journal.pone.0023621.t005
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expression were at significantly increased risk of overall mortality.
These results were consistent with the opinion that the PD-1/PD-
L1 pathway might, at least in part, contribute to the profile of
immunosuppression observed in patients with HCC. These
findings also confirmed that PD-1/PD-L1 was one of the
immunoinhibitory targets for tumor cell.
Taken together, our study suggested that upregulation of
circulating PD-1/PD-L1 could serve as novel valid immunological
markers in predicting disease progression of HCC patients after
cryoablation; and this would be helpful for the improved clinical
management and the development of new therapeutic options for
patient with HBV-related HCC. We postulate that the combina-
tion of cryoablation and immunotherapy such as anti-PD1
antibody [43] may provide a better prognosis for patients with
HCC.
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